In the context of prostate cancer, MV was confirmed to efficiently kill PC-3, DU-145, and LNCaP prostate cancer cell lines, CEA expressing MV vectors generated significant tumor growth delay and prolonged survival after intratumoral administration in mice with subcutaneous PC-3 xenografts [109]. Here, CEACAM5 is linked to prostate carcinoma.